中新集團(601512.SH):擬出資不超過7000萬元參投元禾原點肆號基金
格隆匯1月8日丨中新集團(601512.SH)公佈,公司擬作為有限合夥人參與投資由蘇州工業園區元禾原點創業投資管理有限公司發起設立的元禾原點肆號基金,並以現金貨幣方式向標的基金出資不超過7000萬元,且佔比不超過最終基金認繳總額的5%,資金來源為公司自有資金。標的基金採用有限合夥形式設立,規模不低於人民幣17億元且不超過人民幣22億元。投資領域:關注前沿科技、與產業相結合的科技應用、新藥研發、診斷試劑和醫療器械、數字療法、AI藥物研發、腦機接口等領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.